Han Gong, PeiHe Zhang, Xingming Hu, Bin Zhang. Integrated multiomic data analysis reveals the clinical significance of TXNIP and contributing to immune microenvironment in triple negative breast cancer.Translational oncology. 2024, 39: 101808
Chu-di Zhang, Li-Hong Jiang, Xue Zhou, Yong-Ping He, Ye Liu, Dong-Ming Zhou, Yao Lv, Ben-Qing Wu, Zheng-Yan Zhao. Synergistic antitumor efficacy of rMV-Hu191 and Olaparib in pancreatic cancer by generating oxidative DNA damage and ROS-dependent apoptosis.Translational oncology. 2024, 39: 101812
Giovanni Marchi, Anna Rajavuori, Mai T N Nguyen, Kaisa Huhtinen, Sinikka Oksa, Sakari Hietanen, Sampsa Hautaniemi, Johanna Hynninen, Jaana Oikkonen. Extensive mutational ctDNA profiles reflect High-grade serous cancer tumors and reveal emerging mutations at recurrence.Translational oncology. 2024, 39: 101814
Xiaorui Wang, Na Li, Minying Zheng, Yongjun Yu, Shiwu Zhang. Acetylation and deacetylation of histone in adipocyte differentiation and the potential significance in cancer.Translational oncology. 2024, 39: 101815
Shuo Xu, Qing-Zhang Tuo, Jie Meng, Xiao-Lei Wu, Chang-Long Li, Peng Lei. Thrombin induces ferroptosis in triple-negative breast cancer through the cPLA2α/ACSL4 signaling pathway.Translational oncology. 2024, 39: 101817
Pedro De Marchi, Leticia Ferro Leal, Luciane Sussuchi da Silva, Rodrigo de Oliveira Cavagna, Flavio Augusto Ferreira da Silva, Vinicius Duval da Silva, Eduardo Ca da Silva, Augusto O Saito, Vladmir C Cordeiro de Lima, Rui Manuel Reis. Gene expression profiles (GEPs) of immuno-oncologic pathways as predictors of response to checkpoint inhibitors in advanced NSCLC.Translational oncology. 2024, 39: 101818
Hana Q Sadida, Alanoud Abdulla, Sara Al Marzooqi, Sheema Hashem, Muzafar A Macha, Ammira S Al-Shabeeb Akil, Ajaz A Bhat. Epigenetic modifications: Key players in cancer heterogeneity and drug resistance.Translational oncology. 2024, 39: 101821